Det anbefales, at andre lægemidler, der associeres med myopati, seponeres midlertidigt under behandlingen med Cubicin, hvis det er muligt, medmindre fordelen ved samtidig administration opvejer risikoen.
It is recommended that other medications associated with myopathy should if possible be temporarily discontinued during treatment with Cubicin unless the benefits of concomitant administration outweigh the risk.